CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 97 enrolled
Drug / intervention
Lasmiditan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04749914
NCT04749914Phase 1Completed

An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers

Eli Lilly and Company·interventional·Posted Feb 11, 2021·Updated Feb 1, 2024

In Brief

A Phase 1 clinical trial evaluating Lasmiditan, Dabigatran Etexilate, and 1 other intervention for Healthy. Completed, enrolled 97 participants across 1 site.

Detailed Summary

The main purpose of the study is to investigate the blood concentrations of dabigatran etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan in healthy participants. The safety and tolerability of dabigatran etexilate or rosuvastatin in combination with lasmiditan will also be evaluated in healthy participants. The study has two parts. Each part will last up to 17 days, not including screening.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedFeb 11, 2021
Enrollment StartFeb 15, 2021
Primary CompletionJul 6, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.4 years ago

Interventions

Lasmiditandrug

Administered orally.

Dabigatran Etexilatedrug

Administered orally.

Rosuvastatindrug

Administered orally.